Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-2173 + Tenofovir Interaction Study
NCT05137548Phase 1Completed
- Sponsor
- Antios Therapeutics
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ATI-2173 in Chronic Hepatitis B (CHB) (2 cohorts), sponsored by Antios Therapeutics. Primary endpoints: Maximum Plasma Concentration (Cmax) of ATI-2173, clevudine, and M1 at 3 months, Area Under the Curve (AUCtau) of ATI-2173, clevudine, and M1 at 3 months and 5 more. Started Oct 2021; status: completed.
02
Drugs
ATI-2173
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05137548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05137548.